Literature DB >> 17934102

Update on toll-like receptor-directed therapies for human disease.

Kevin Tse1, Anthony A Horner.   

Abstract

Innate responses to microbes are mediated in large part by toll-like receptors (TLRs), which recognise a diverse range of molecules produced by viruses, bacteria and fungi. Great effort has been directed towards translating this knowledge into the development of new therapies for a wide spectrum of diseases, including infectious, malignant, autoimmune and allergic diseases. This review will provide a brief update on completed, ongoing and planned clinical trials of TLR ligand-based therapies for the treatment of diseases in humans.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17934102      PMCID： PMC2095280          DOI： 10.1136/ard.2007.078998

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  57 in total

1.  Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.

Authors:  Melvyn Lynn; Daniel P Rossignol; Janice L Wheeler; Richard J Kao; Carlos A Perdomo; Robert Noveck; Ramon Vargas; Tony D'Angelo; Sandra Gotzkowsky; F Gilbert McMahon
Journal:  J Infect Dis       Date:  2003-02-07       Impact factor: 5.226

Review 2.  TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway.

Authors:  Paul N Moynagh
Journal:  Trends Immunol       Date:  2005-09       Impact factor: 16.687

3.  Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.

Authors:  Maureen Mullarkey; Jeffrey R Rose; John Bristol; Tsutomu Kawata; Akufumi Kimura; Seiichi Kobayashi; Melinda Przetak; Jesse Chow; Fabian Gusovsky; William J Christ; Daniel P Rossignol
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

4.  Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice.

Authors:  Kenji Takabayashi; Lev Libet; Dugald Chisholm; Jose Zubeldia; Anthony A Horner
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

Review 5.  Hygiene hypothesis: fact or fiction?

Authors:  Andrew H Liu; James R Murphy
Journal:  J Allergy Clin Immunol       Date:  2003-03       Impact factor: 10.793

6.  Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity.

Authors:  Anthony A Horner; Kenji Takabayashi; Lucinda Beck; Bhavya Sharma; Jose Zubeldia; Stephen Baird; Stephan Tuck; Lev Libet; Hans L Spiegelberg; Fu-Tong Liu; Eyal Raz
Journal:  J Allergy Clin Immunol       Date:  2002-09       Impact factor: 10.793

7.  Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities.

Authors:  Dugald Chisholm; Lev Libet; Tomoko Hayashi; Anthony A Horner
Journal:  J Allergy Clin Immunol       Date:  2004-03       Impact factor: 10.793

8.  Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response.

Authors:  Meri K Tulic; Pierre-Olivier Fiset; Pota Christodoulopoulos; Patrice Vaillancourt; Martin Desrosiers; François Lavigne; Joseph Eiden; Qutayba Hamid
Journal:  J Allergy Clin Immunol       Date:  2004-02       Impact factor: 10.793

9.  A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.

Authors:  Scott A Halperin; Gary Van Nest; Bruce Smith; Simin Abtahi; Heather Whiley; Joseph J Eiden
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

10.  Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen.

Authors:  Stephanie C Eisenbarth; Damani A Piggott; James W Huleatt; Irene Visintin; Christina A Herrick; Kim Bottomly
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307
View more
  8 in total

1.  The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators.

Authors:  Whitney Valins; Sadegh Amini; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-09

Review 2.  The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

Authors:  Abbi L Engel; Gregory E Holt; Hailing Lu
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

3.  Helminth cysteine proteases inhibit TRIF-dependent activation of macrophages via degradation of TLR3.

Authors:  Sheila Donnelly; Sandra M O'Neill; Colin M Stack; Mark W Robinson; Lynne Turnbull; Cynthia Whitchurch; John P Dalton
Journal:  J Biol Chem       Date:  2009-11-18       Impact factor: 5.157

4.  Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA.

Authors:  Takeshi Saito; David M Owen; Fuguo Jiang; Joseph Marcotrigiano; Michael Gale
Journal:  Nature       Date:  2008-06-11       Impact factor: 49.962

Review 5.  Toll-Like Receptors in the Pathogenesis of Autoimmune Diseases.

Authors:  Akbar Mohammad Hosseini; Jafar Majidi; Behzad Baradaran; Mehdi Yousefi
Journal:  Adv Pharm Bull       Date:  2015-12-31

6.  Toll-like receptors in autoimmunity with special reference to systemic lupus erythematosus.

Authors:  Vandana D Pradhan; Swaptagni Das; Prathamesh Surve; Kanjaksha Ghosh
Journal:  Indian J Hum Genet       Date:  2012-05

Review 7.  Metal-Based Nanoparticles and the Immune System: Activation, Inflammation, and Potential Applications.

Authors:  Yueh-Hsia Luo; Louis W Chang; Pinpin Lin
Journal:  Biomed Res Int       Date:  2015-06-01       Impact factor: 3.411

Review 8.  NF-kB as a key player in regulation of cellular radiation responses and identification of radiation countermeasures.

Authors:  Vijay Singh; Damodar Gupta; Rajesh Arora
Journal:  Discoveries (Craiova)       Date:  2015-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.